Trial Outcomes & Findings for Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy (NCT NCT02649322)

NCT ID: NCT02649322

Last Updated: 2020-05-05

Results Overview

Pain will be assessed via the Visual Analog Scale by the patient before administration of the nerve block. Patient will report on a scale of 0 to 10 what their perceived pain is. 0 is no pain with 10 being worst pain patient ever experienced.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

115 participants

Primary outcome timeframe

During Baseline Assessment, Taking Approximately 20 Minutes, Before Nerve Block

Results posted on

2020-05-05

Participant Flow

Participant milestones

Participant milestones
Measure
Group A Lidocaine J-Tip
Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure. J-Tip: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
Group B Lidocaine Syringe
Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure. Syringe and 25 gauge needle: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Overall Study
STARTED
58
57
Overall Study
COMPLETED
58
57
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group A Lidocaine J-Tip
n=58 Participants
Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure. J-Tip: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
Group B Lidocaine Syringe
n=57 Participants
Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure. Syringe and 25 gauge needle: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Total
n=115 Participants
Total of all reporting groups
Age, Categorical
<=18 years
58 Participants
n=5 Participants
57 Participants
n=7 Participants
115 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
15 years
n=5 Participants
14 years
n=7 Participants
15 years
n=5 Participants
Sex: Female, Male
Female
29 Participants
n=5 Participants
32 Participants
n=7 Participants
61 Participants
n=5 Participants
Sex: Female, Male
Male
29 Participants
n=5 Participants
25 Participants
n=7 Participants
54 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
9 Participants
n=5 Participants
9 Participants
n=7 Participants
18 Participants
n=5 Participants
Race (NIH/OMB)
White
25 Participants
n=5 Participants
24 Participants
n=7 Participants
49 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
24 Participants
n=5 Participants
23 Participants
n=7 Participants
47 Participants
n=5 Participants
Region of Enrollment
United States
58 participants
n=5 Participants
57 participants
n=7 Participants
115 participants
n=5 Participants
Participants
58 Participants
n=5 Participants
57 Participants
n=7 Participants
115 Participants
n=5 Participants

PRIMARY outcome

Timeframe: During Baseline Assessment, Taking Approximately 20 Minutes, Before Nerve Block

Population: Comparison of the mean pain on visual analog scale

Pain will be assessed via the Visual Analog Scale by the patient before administration of the nerve block. Patient will report on a scale of 0 to 10 what their perceived pain is. 0 is no pain with 10 being worst pain patient ever experienced.

Outcome measures

Outcome measures
Measure
Group A Lidocaine J-Tip
n=58 Participants
Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure. J-Tip: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
Group B Lidocaine Syringe
n=57 Participants
Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure. Syringe and 25 gauge needle: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Baseline Pain Assessment Before Knee Arthroscopy Via the Visual Analog Scale.
.25 score on a scale
Standard Deviation 1.243
.43 score on a scale
Standard Deviation 1.185

PRIMARY outcome

Timeframe: During Follow-up Assessment at an Average of 1 Week Post Op

Population: Comparison of the mean pain on visual analog scale

Pain will be assess via the Visual Analog Scale by the patient after the knee arthroscopy though first post op office visit and average of one week. Patient will report on a scale of 0 to 10 what their perceived pain is. 0 is no pain with 10 being worst pain patient ever experienced.

Outcome measures

Outcome measures
Measure
Group A Lidocaine J-Tip
n=58 Participants
Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure. J-Tip: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
Group B Lidocaine Syringe
n=57 Participants
Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure. Syringe and 25 gauge needle: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Pain Assessment After Knee Arthroscopy Via the Visual Analog Scale
1.54 units on a scale
Standard Deviation 1.524
3.57 units on a scale
Standard Deviation 2.133

SECONDARY outcome

Timeframe: At the follow up appointment, an average of one week after the procedure.

Population: Comparison of the mean satisfaction on visual analog scale

Patients will be asked to describe how satisfied they were with the knee arthroscopy via a 0 to 10 rating scale. Patient will report on a scale of 0 to 10 what their perceived satisfaction is. 0 is no satisfaction with 10 most satisfaction.

Outcome measures

Outcome measures
Measure
Group A Lidocaine J-Tip
n=58 Participants
Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure. J-Tip: After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
Group B Lidocaine Syringe
n=57 Participants
Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure. Syringe and 25 gauge needle: The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
Satisfaction Via a 0 to 10 Rating Scale at Follow up
2.384615385 score on a scale
Standard Deviation 1.796149728
2.391304348 score on a scale
Standard Deviation 2.623999904

Adverse Events

Group A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group B

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Daryl C. Osbahr, MD

Orlando Health

Phone: 321.843.4800

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place